Arisa Akashi Sin
Lawyers

Filters
Precigen $129 million common stock offering
We advised the underwriters in connection with the SEC-registered equity offering
Hamilton Lane Alliance Holdings I $270 million IPO
We advised the underwriters on the SPAC IPO and NYSE listing
LendingTree $872 million secondary offering
Davis Polk advised LendingTree, Inc. in connection with the $872 million secondary offering of 2,955,984 shares of its common stock by Ventures Holdco II, LLC, which is a wholly owned…
VG Acquisition $480 million IPO
Davis Polk advised VG Acquisition Corp. on its $480 million initial public offering of 48,000,000 units. Each unit had an initial offering price of $10 and consists of one Class A ordinary…
Gilead Sciences $7.25 billion senior notes offering
Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…
Broadstone Acquisition $300 million IPO
Davis Polk advised the underwriter in connection with the initial public offering of 30,000,000 units of Broadstone Acquisition Corp., for aggregate proceeds of $300 million. Each unit…
Prime Impact Acquisition I $300 million IPO
Davis Polk advised the underwriters in connection with the initial public offering of 30,000,000 units of Prime Impact Acquisition I, for aggregate proceeds of $300 million. Each unit…
Constellation Pharmaceuticals $192.5 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $192.5 million offering of common stock of Constellation…
Werner Enterprises $579 million secondary offering
Davis Polk advised the representative of the several underwriters in connection with an underwritten secondary offering of 14,130,523 shares of common stock of Werner Enterprises, Inc. by…
Biogen $3 billion senior notes offering
Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.250% senior notes due 2030…